Sarah B. Goldberg, MD, MPH | Authors

September 03, 2019

Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as EGFR, ALK, BRAF,ROS1, or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.

May 16, 2017

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.